BD Board Increases Dividend for 53rd Consecutive Year
Rhea-AI Summary
BD (NYSE: BDX) has announced a 9.5% increase in its quarterly dividend to $1.04 per common share, payable on December 31, 2024, to shareholders of record on December 9, 2024. This marks the company's 53rd consecutive year of dividend increases, maintaining its position in the S&P 500 Dividend Aristocrats Index. The indicated annual dividend rate for fiscal year 2025 is set at $4.16 per share. Management attributes this increase to confidence in their long-term outlook and commitment to shareholder value through their BD 2025 strategy.
Positive
- Substantial 9.5% increase in quarterly dividend
- 53-year track record of consecutive dividend increases
- Maintains position in S&P 500 Dividend Aristocrats Index
- Annual dividend rate increased to $4.16 per share for FY2025
- Management expresses confidence in long-term outlook
Negative
- None.
"This is the 53rd consecutive fiscal year in which we have raised our dividend, maintaining BD's membership in the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends for at least 25 consecutive years," said Tom Polen, chairman, CEO and president of BD. "This increase reflects our confidence in our long-term outlook, as well as our ongoing commitment to create value through execution of our BD 2025 strategy and return capital to shareholders."
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts: | |
Media: | Investors: |
Troy Kirkpatrick | Adam Reiffe |
VP, Public Relations | Sr. Director, Investor Relations |
858.617.2361 | 201.847.6927 |
View original content:https://www.prnewswire.com/news-releases/bd-board-increases-dividend-for-53rd-consecutive-year-302298075.html
SOURCE BD (Becton, Dickinson and Company)